FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care

Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.

Last reviewed: 7 June 2023

This guidance replaces NICE’s medtech innovation briefing on FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216).

Diagnostics guidance 48 has been migrated to HealthTech guidance 682.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Guidance development process

How we develop NICE HealthTech guidance